Cybrexa
Latest round
- Series B
Last raised
- Mar 2021
Total raised
- $44M
Investors
- 4
About Cybrexa
Founded in 2017 and based in Connecticut, US, Cybrexa, Inc. operates as a biotechnology company that focuses on developing alphalex™, a health technology platform that aims to target tumor cells. The company was founded by its CEO Per Hellsund. In January 2020, Cybrexa, Inc. Cybrexa’s alphalex™ is a tumor-targeting platform that can be used to improve new applications and combinations of existing cancer therapeutics with its targeted intracellular drug delivery technology. By using alphalex™'s tumor-localizing peptide technology, Cybrexa is developing a new class of small molecule DNA repair inhibitors that could directly target the tumor microenvironment and cure them. The company has a pipeline program called CBX-12 that is a clinical trial for the treatment of solid tumors by using a highly potent topoisomerase I inhibitor exatecan payload. As of March 2021, the CBX-12 is being investigated in collaboration with NCI in pre-clinical safety and efficacy study. The company’s future strategy includes supporting the planned advancement of its lead candidate CBX-12 (alphalex™-exatecan) into the clinic.
Who invested in Cybrexa
4 investors across 3 rounds
See all investors in Cybrexa
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Cybrexa
Who invested in Cybrexa?
Cybrexa has 4 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cybrexa raised?
Cybrexa has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Cybrexa last raise money?
Cybrexa's most recent round on record is a Series B, in Mar 2021.
What does Cybrexa do?
Founded in 2017 and based in Connecticut, US, Cybrexa, Inc.
Where is Cybrexa headquartered?
Cybrexa is headquartered in New Haven, US.
Which VCs invest in companies like Cybrexa?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Cybrexa's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Cybrexa? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.